NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018

Horwitz, Steven M.; Ansell, Stephen M.; Ai, Weiyun Z.; Barnes, Jeffrey A.; Barta, Stefan K.; Choi, Michael Y.; Clemens, Mark W.; Doğan, Ahmet; Greer, John P.; Halwani, Ahmad; Haverkos, Bradley M.; Hoppe, Richard T.; Jacobsen, Eric; Jagadeesh, Deepa; Kim, Youn H.; Lunning, Matthew A.; Mehta, Amitkumar; Mehta‐Shah, Neha; Oki, Y.; Olsen, Elise A.; Pro, Barbara; Rajguru, Saurabh; Shanbhag, Satish; Shustov, Andrei R.; Sokol, Lubomir; Torka, Pallawi; Wilcox, Ryan A.; William, Basem M.; Zain, Jasmine; Dwyer, Mary A.; Sundar, Hema

doi:10.6004/jnccn.2018.0007

Cited by 52 publications

(42 citation statements)

References 49 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the National Comprehensive Cancer Network guideline recommends the evaluation of EBER1 ISH in BM when the specimen is morphologically negative for involvement of ENKL, and patients with one or more EBER1‐positive cells in BM specimen are thought to have advanced‐stage disease.…”

Section: Discussionmentioning

confidence: 99%

“…13,14 On the other hand, the current standard-of-care in advanced-stage ENKL is induction therapy with an intensive L-asparaginase-containing regimen, such as dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) therapy, followed by consolidative therapy with hematopoietic stem cell transplantation; the 5-year OS and PFS are 47% and 39%, respectively. 15,16 Currently, the National Comprehensive Cancer Network guideline recommends the evaluation of EBER1 ISH in © 2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd Table 2 Correlation between the total number of EBER1-positive cells in each bone marrow specimen and age, sex, or disease BM when the specimen is morphologically negative for involvement of ENKL, 10 and patients with one or more EBER1-positive cells in BM specimen are thought to have advanced-stage disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

EBV‐encoded RNA1‐positive cells in the bone marrow specimens of patients with EBV‐negative lymphomas and sarcomas

Ito¹,

Makita²,

Maeshima³

et al. 2019

Pathology International

View full text Add to dashboard Cite

Epstein‐Barr virus (EBV) infection is associated with pathogenesis of various cancers, including extranodal natural killer/T‐cell lymphoma, nasal type (ENKL). ENKL tumor cells are positive for EBV‐encoded RNA1 (EBER1), which is the most useful marker to identify ENKL tumor cells in histopathology. Currently, EBER1 in situ hybridization (ISH) is recommended to evaluate bone marrow (BM) involvement of ENKL. However, the actual burden of EBER1‐positive cells in normal BM specimens remains unclear. In the present study, we performed EBER1 ISH on 111 BM specimens, which were obtained during an initial staging procedure in patients with EBV‐negative cancers and were also negative for BM involvement. One or more EBER1‐positive cells per whole specimen were observed in 38 specimens (34%). The number of EBER1‐positive cells was distributed as follows: single positive cell, n = 17; two positive cells, n = 13; three positive cells, n = 3; and four positive cells, n = 5. These findings suggest that four or fewer EBER1‐positive cells can be observed in BM specimens of patients with non‐EBV‐related cancers. The clinical implications of a small number of EBER1‐positive cells in BM specimens of patients with ENKL should be evaluated in further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

EBV‐encoded RNA1‐positive cells in the bone marrow specimens of patients with EBV‐negative lymphomas and sarcomas

Ito¹,

Makita²,

Maeshima³

et al. 2019

Pathology International

View full text Add to dashboard Cite

show abstract

“…After being validated in the most common cancer subtypes, some of these approaches are now being tested in rare neoplasms such as T cell lymphoma (TCL) and leukemia (T-ALL). The need for effective and safe new therapies is urgent, as the overall prognosis for these rare diseases is generally poor (5, 6). …”

Section: Introductionmentioning

confidence: 99%

“…Overall, TCL represent about 10% of all non-Hodgkin’s lymphomas (NHL) (7). PTCL-not otherwise specified (PTCL-NOS) is the most common subtype (26%), followed by angioimmunoblastic TCL (AITL, 19%), anaplastic large cell lymphoma (ALCL) divided into anaplastic lymphoma kinase (ALK) positive (7%), and ALK negative (6%) and enteropathy-associated TCL (EATL; <5%) (5, 8). The majority of PTCL originate from the CD4+ helper cells while only a minority of PTCL is derived from the CD8+ cytotoxic cells.…”

Section: Introductionmentioning

confidence: 99%

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Ghione

Moskowitz

Paola

et al. 2018

Curr Hematol Malig Rep

Self Cite

View full text Add to dashboard Cite

Purpose of review: novel immunotherapies such as checkpoint inhibitors, bispecific and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells. These are rare diseases with generally poor clinical outcomes. This review describes the rational and preliminary results of these approaches for people with T cell lymphoma and leukemia. Recent findings: for T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. Summary: In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.

show abstract

“…Recently published national and international treatment guidelines are used to inform treatment selection on the basis of patients' clinical condition and tumor stage [7,[11][12][13][14]. Many topical and systemic therapies have been developed in recent decades.…”

Section: Current Therapeutic Options For Pctclmentioning

confidence: 99%

Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma

Elsayad

Susek

Eich³

2017

Oncol Res Treat

View full text Add to dashboard Cite

Total-skin electron beam therapy (TSEBT) is one of most effective treatments that has been used for cutaneous T-cell lymphoma. Low-dose TSEBT regimens (10-12 Gy) appear to be an effective alternative to conventional-dose TSEBT (30-36 Gy), yielding short-term remission of cutaneous manifestations with minimal toxicity. TSEBT can be administered to patients any time after a diagnosis of mycosis fungoides (MF). Patients requiring rapid relief from cutaneous lesions or symptoms may particularly benefit from TSEBT as an initial therapy. Radiotherapy (RT) dose, boost radiation delivery, maintenance treatment, and radiation tolerability may enhance remission rates and improve relapse-free survival following TSEBT. In addition, salvage local RT or TSEBT may be safely applied with high effectiveness. In this review, we focus on the use of TSEBT in patients with several forms of primary cutaneous T-cell lymphoma, and highlight the potential of low-dose TSEBT as part of a promising therapeutic approach.

show abstract

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018

Cited by 52 publications

References 49 publications

EBV‐encoded RNA1‐positive cells in the bone marrow specimens of patients with EBV‐negative lymphomas and sarcomas

EBV‐encoded RNA1‐positive cells in the bone marrow specimens of patients with EBV‐negative lymphomas and sarcomas

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About